Viatris announced that six abstracts related to its investigational low-dose estrogen combined hormonal contraceptive weekly patch will be presented at a major OB-GYN meeting. This highlights progress in the development and potential market introduction of the new birth control product.
Viatris Weekly Contraceptive Patch Data to Feature at OB-GYN Meeting
ViatrisPharmaceuticalsBiotechClinical DataWomen's Health



